Pelthos Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | ||
| Net product revenues | $10,665 | $— |
| License and collaboration revenues | 241 | — |
| Total revenue | 10,906 | — |
| Operating expenses | ||
| Cost of goods sold | 1,673 | — |
| Selling, general and administrative | 21,104 | 1,640 |
| Research and development | 186 | 194 |
| Amortization of intangible assets | 1,031 | — |
| Total operating expenses | 23,994 | 1,834 |
| Operating loss | (13,088) | (1,834) |
| Other (expense) income | ||
| Interest expense | (2,353) | (134) |
| Change in fair value of convertible debt | 5,203 | — |
| Total other (expense) income | 2,850 | (134) |
| Net loss before provision for income taxes | (10,238) | (1,968) |
| Provision for income taxes | — | — |
| Net loss | $(10,238) | $(1,968) |
| Other comprehensive income: | ||
| Change in fair value of convertible debt due to instrument credit risk | 3,189 | — |
| Comprehensive loss | $(7,049) | $(1,968) |
| Net loss per common share - basic and diluted | $(3.09) | $(3.21) |
| Weighted average number of common shares outstanding - basic and diluted | 3,311,742 | 612,889 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.